HER2+ (Positive) Breast Cancer
Archives for September 2021
Discussion List
-
Enhertu Way More Effective Than Kadcyla as 2nd Tx for HER2+ MBC
Enhertu Dramatically More Effective Than Kadcyla as Second Treatment for Metastatic HER2-Positive Breast Cancer September 22, 2021 Enhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. Read more...
Join Us on Zoom: Upcoming virtual meetups. Read more...